Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
- PMID: 30464590
- PMCID: PMC6208494
- DOI: 10.2147/CMAR.S179368
Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
Erratum in
-
Erratum: Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum].Cancer Manag Res. 2024 Jan 25;16:71-72. doi: 10.2147/CMAR.S455833. eCollection 2024. Cancer Manag Res. 2024. PMID: 38293291 Free PMC article.
Expression of concern in
-
Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Expression of Concern].Cancer Manag Res. 2023 Apr 18;15:365-366. doi: 10.2147/CMAR.S417556. eCollection 2023. Cancer Manag Res. 2023. PMID: 37095768 Free PMC article. No abstract available.
Abstract
Background: Whether palliative gastrectomy combined with chemotherapy can improve the survival of patients with advanced gastric cancer remains controversial. We performed a meta-analysis to clarify whether palliative gastrectomy plus chemotherapy can benefit patients with incurable advanced gastric cancer and to explore the best candidates in this patient population.
Methods: We searched the literature systematically using electronic databases including PubMed, EMBASE, and the Cochrane Library. And HRs and their 95% CIs were used to express the results for overall survival (OS) and progression-free survival (PFS).
Results: One randomized controlled trial with 175 patients and 12 cohort studies with 2,193 patients were analyzed. The pooled HR for OS (HR=0.43, 95% CI=0.29-0.65, P<0.001), subgroup analysis of stage M1 (HR=0.53, 95% CI=0.40-0.72, P<0.001), peritoneal dissemination (HR=0.46, 95% CI=0.28-0.73, P=0.001), and liver metastasis (HR=0.46, 95% CI=0.33-0.65, P<0.001) all indicated the superiority of palliative gastrectomy plus chemotherapy. However, the pooled HR for PFS (HR=0.61, 95% CI=0.33-1.13, P=0.110) got separate outcome.
Conclusion: The results of this meta-analysis indicated that palliative gastrectomy plus chemotherapy can improve OS for incurable advanced gastric cancer. In addition, analyses based on liver metastasis and peritoneal dissemination demonstrated the advantages of palliative gastrectomy plus chemotherapy. However, the PFS of incurable advanced gastric cancer with palliative gastrectomy plus chemotherapy was no better than that under chemotherapy alone.
Keywords: advanced gastric cancer; chemotherapy; palliative gastrectomy; survival.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures










Similar articles
-
Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis.Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2299-2312. doi: 10.26355/eurrev_202103_25262. Eur Rev Med Pharmacol Sci. 2021. PMID: 33755967
-
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26. Lancet Oncol. 2016. PMID: 26822397 Clinical Trial.
-
Comparison of the Efficacy of D2 Gastrectomy Plus Liver Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone in the Treatment of Advanced Gastric Cancer With Unresectable Synchronous Liver Metastases: A Multicenter Randomized Controlled Trial Protocol.Front Oncol. 2022 Feb 28;12:802683. doi: 10.3389/fonc.2022.802683. eCollection 2022. Front Oncol. 2022. PMID: 35296006 Free PMC article.
-
The prognostic role of palliative gastrectomy in advanced gastric cancer: a systematic review and meta-analysis.BMC Cancer. 2024 Sep 3;24(1):1096. doi: 10.1186/s12885-024-12860-z. BMC Cancer. 2024. PMID: 39227821 Free PMC article.
-
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Oct 1;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312. JAMA Netw Open. 2020. PMID: 33048129 Free PMC article.
Cited by
-
Treatment of Synchronous Liver Metastases from Gastric Cancer: A Single-Center Study.Cancer Manag Res. 2020 Aug 26;12:7905-7911. doi: 10.2147/CMAR.S261353. eCollection 2020. Cancer Manag Res. 2020. PMID: 32904676 Free PMC article.
-
Application and progress of palliative therapy in advanced gastric carcinomas.Front Oncol. 2023 Mar 9;13:1104447. doi: 10.3389/fonc.2023.1104447. eCollection 2023. Front Oncol. 2023. PMID: 36969008 Free PMC article. Review.
-
Estimating the treatment effect in patients with gastric cancer in the presence of noncompliance.Gastroenterol Hepatol Bed Bench. 2021 Summer;14(3):206-214. Gastroenterol Hepatol Bed Bench. 2021. PMID: 34221259 Free PMC article.
-
HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study.BMC Surg. 2021 Jul 12;21(1):308. doi: 10.1186/s12893-021-01307-y. BMC Surg. 2021. PMID: 34253213 Free PMC article.
References
-
- Thrumurthy SG, Chaudry MA, Chau I, Allum W. Does surgery have a role in managing incurable gastric cancer? Nat Rev Clin Oncol. 2015;12(11):676–682. - PubMed
-
- Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol. 2011;106(11):1978–1985. - PubMed
-
- Ajani JA, Bentrem DJ, National Comprehensive Cancer Network Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):531–546. - PubMed
-
- Japanese GCA, Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2010 (ver. 3) Gastric Cancer. 2011;14(2):113–123. - PubMed
LinkOut - more resources
Full Text Sources